This year’s American Association of Immunologists AAI annual meeting in Boston featured a standout sponsored session from the Cytokine Society, bringing together a diverse and highly engaged cross section of the cytokine research community. Titled “Translating Human Immunology Through Cytokine Research,” the session highlighted the breadth of the field, from fundamental mechanisms of cytokine driven immune function to emerging therapeutic strategies and early clinical results. Presentations spanned inflammasome pathway inhibition in autoinflammatory disease (Michael Badman, Novartis), boosting innate immune adjuvants (Ivan Zanoni, Boston Children’s Hospital and Harvard Medical School), cytokine signaling dynamics in gene regulation (Rachel Gottschalk, University of Pittsburgh), development of an mRNA platform to an emerging immunology pipeline (Kate Jeffrey, Moderna), and multifunctional antibody approaches for type 2 cytokine driven disease (Thomas Wynn, Pfizer).
A defining feature was the interplay between academic and industry perspectives, underscoring that translating cytokine biology into therapies requires not only mechanistic insight but also expertise in development, safety, and clinical strategy. The standing room only audience and lively discussions reflected strong demand for this cross-sector exchange. Co-chaired by Kate Jeffrey and Rachel Gottschalk, the session also highlighted the upcoming Cytokine Society meeting in Glasgow and reinforced the importance of continuing to attract members from both academia and industry. Maintaining this balance ensures the Society remains a forum where discovery and application inform one another, strengthening the path from basic cytokine biology to patient impact.